Welcome to our dedicated page for Catalyst Pharmaceuticals news (Ticker: CPRX), a resource for investors and traders seeking the latest updates and insights on Catalyst Pharmaceuticals stock.
Catalyst Pharmaceuticals reports developments as a commercial-stage biopharmaceutical company focused on in-licensing, developing, and commercializing medicines for rare and difficult-to-treat diseases. Its recurring updates center on the commercial performance of FIRDAPSE® (amifampridine), AGAMREE® (vamorolone), and FYCOMPA® (perampanel), along with financial results, revenue guidance, conference presentations, and business updates.
Company news also covers product-specific medical and legal developments, including vamorolone research in Duchenne muscular dystrophy and patent litigation settlements involving FIRDAPSE. Additional announcements address patient advocacy initiatives, support services, and strategic portfolio activity tied to Catalyst’s U.S.-based rare-disease commercial model.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.